Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you manage T3N0M0 sarcomatoid carcinoma of the prostate with Adenosquamous differentiation s/p prostatectomy?
Any role for adjuvant therapy with chemotherapy, ADT or radiation?
Related Questions
What are your top takeaways from ASCO GU 2025?
How do you manage prostate cancer in patients that cannot swallow pills?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?